Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

STXBP1 encephalopathy: Connecting neurodevelopmental disorders with α-synucleinopathies?

Lanoue V, Chai YJ, Brouillet JZ, Weckhuysen S, Palmer EE, Collins BM, Meunier FA.

Neurology. 2019 Jul 16;93(3):114-123. doi: 10.1212/WNL.0000000000007786. Epub 2019 Jun 20. Review.

PMID:
31221716
2.

Relevance of total PSA and free PSA prescriptions.

Lamy PJ, Brouillet JP, Bermont L, Fouillet G, Loric S.

Ann Biol Clin (Paris). 2018 Dec 1;76(6):659-663. doi: 10.1684/abc.2018.1392. Review.

PMID:
30543191
3.

Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability.

Mbatchi LC, Brouillet JP, Evrard A.

Pharmacogenomics. 2018 Jan;19(1):61-77. doi: 10.2217/pgs-2017-0121. Epub 2017 Dec 4. Review.

PMID:
29199543
4.

Primary stenting for TASC C and D femoropopliteal lesions: one-year results from a multicentric trial on 203 patients.

Brouillet J, Deloose K, Goueffic Y, Poirier M, Midy D, Caradu C, Ducasse E.

J Cardiovasc Surg (Torino). 2018 Jun;59(3):392-404. doi: 10.23736/S0021-9509.16.09282-X. Epub 2016 Jun 7.

PMID:
27272981
5.

Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.

Mbatchi LC, Schmitt A, Thomas F, Cazaubon Y, Robert J, Lumbroso S, Brouillet JP, Pourquier P, Chatelut E, Boyer JC, Evrard A.

Pharmacogenomics. 2015;16(13):1439-50. doi: 10.2217/pgs.15.84. Epub 2015 Aug 12.

PMID:
26267044
6.

A common polymorphism in NR1H2 (LXRbeta) is associated with preeclampsia.

Mouzat K, Mercier E, Polge A, Evrard A, Baron S, Balducchi JP, Brouillet JP, Lumbroso S, Gris JC.

BMC Med Genet. 2011 Oct 26;12:145. doi: 10.1186/1471-2350-12-145.

7.

Smile esthetics: a methodology for success in a complex case.

Paris JC, Ortet S, Larmy A, Brouillet JL, Faucher AJ.

Eur J Esthet Dent. 2011 Spring;6(1):50-74.

PMID:
21403927
8.

Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project.

Gerstein MB, Lu ZJ, Van Nostrand EL, Cheng C, Arshinoff BI, Liu T, Yip KY, Robilotto R, Rechtsteiner A, Ikegami K, Alves P, Chateigner A, Perry M, Morris M, Auerbach RK, Feng X, Leng J, Vielle A, Niu W, Rhrissorrakrai K, Agarwal A, Alexander RP, Barber G, Brdlik CM, Brennan J, Brouillet JJ, Carr A, Cheung MS, Clawson H, Contrino S, Dannenberg LO, Dernburg AF, Desai A, Dick L, Dosé AC, Du J, Egelhofer T, Ercan S, Euskirchen G, Ewing B, Feingold EA, Gassmann R, Good PJ, Green P, Gullier F, Gutwein M, Guyer MS, Habegger L, Han T, Henikoff JG, Henz SR, Hinrichs A, Holster H, Hyman T, Iniguez AL, Janette J, Jensen M, Kato M, Kent WJ, Kephart E, Khivansara V, Khurana E, Kim JK, Kolasinska-Zwierz P, Lai EC, Latorre I, Leahey A, Lewis S, Lloyd P, Lochovsky L, Lowdon RF, Lubling Y, Lyne R, MacCoss M, Mackowiak SD, Mangone M, McKay S, Mecenas D, Merrihew G, Miller DM 3rd, Muroyama A, Murray JI, Ooi SL, Pham H, Phippen T, Preston EA, Rajewsky N, Rätsch G, Rosenbaum H, Rozowsky J, Rutherford K, Ruzanov P, Sarov M, Sasidharan R, Sboner A, Scheid P, Segal E, Shin H, Shou C, Slack FJ, Slightam C, Smith R, Spencer WC, Stinson EO, Taing S, Takasaki T, Vafeados D, Voronina K, Wang G, Washington NL, Whittle CM, Wu B, Yan KK, Zeller G, Zha Z, Zhong M, Zhou X; modENCODE Consortium, Ahringer J, Strome S, Gunsalus KC, Micklem G, Liu XS, Reinke V, Kim SK, Hillier LW, Henikoff S, Piano F, Snyder M, Stein L, Lieb JD, Waterston RH.

Science. 2010 Dec 24;330(6012):1775-87. doi: 10.1126/science.1196914. Epub 2010 Dec 22. Erratum in: Science. 2011 Jan 7;331(6013):30.

9.

Gene expression profiling in head and neck squamous cell carcinoma: Clinical perspectives.

Lallemant B, Evrard A, Chambon G, Sabra O, Kacha S, Lallemant JG, Lumbroso S, Brouillet JP.

Head Neck. 2010 Dec;32(12):1712-9. doi: 10.1002/hed.21491. Review.

PMID:
20949446
10.

Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.

Raynal C, Pascussi JM, Leguelinel G, Breuker C, Kantar J, Lallemant B, Poujol S, Bonnans C, Joubert D, Hollande F, Lumbroso S, Brouillet JP, Evrard A.

Mol Cancer. 2010 Mar 2;9:46. doi: 10.1186/1476-4598-9-46.

11.

High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.

Raynal C, Ciccolini J, Mercier C, Boyer JC, Polge A, Lallemant B, Mouzat K, Lumbroso S, Brouillet JP, Evrard A.

Ther Drug Monit. 2010 Feb;32(1):53-60. doi: 10.1097/FTD.0b013e3181c77c1b.

PMID:
20010457
12.

Clinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse.

Lallemant B, Evrard A, Combescure C, Chapuis H, Chambon G, Raynal C, Reynaud C, Sabra O, Joubert D, Hollande F, Lallemant JG, Lumbroso S, Brouillet JP.

BMC Cancer. 2009 Oct 18;9:370. doi: 10.1186/1471-2407-9-370.

13.

Reference gene selection for head and neck squamous cell carcinoma gene expression studies.

Lallemant B, Evrard A, Combescure C, Chapuis H, Chambon G, Raynal C, Reynaud C, Sabra O, Joubert D, Hollande F, Lallemant JG, Lumbroso S, Brouillet JP.

BMC Mol Biol. 2009 Aug 3;10:78. doi: 10.1186/1471-2199-10-78.

14.
15.

Twenty years' monitoring of Mèze stabilisation ponds: part II--Removal of faecal indicators.

Brissaud F, Andrianarison T, Brouillet JL, Picot B.

Water Sci Technol. 2005;51(12):33-41.

PMID:
16114661
16.

Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients.

Alix-Panabières C, Rebillard X, Brouillet JP, Barbotte E, Iborra F, Segui B, Maudelonde T, Jolivet-Reynaud C, Vendrell JP.

Clin Chem. 2005 Aug;51(8):1538-41. No abstract available.

17.

Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients.

Alix-Panabières C, Brouillet JP, Fabbro M, Yssel H, Rousset T, Maudelonde T, Choquet-Kastylevsky G, Vendrell JP.

J Immunol Methods. 2005 Apr;299(1-2):177-88. Epub 2005 Apr 12.

PMID:
15914200
18.

Six novel heterozygous MLH1, MSH2, and MSH6 and one homozygous MLH1 germline mutations in hereditary nonpolyposis colorectal cancer.

Rey JM, Noruzinia M, Brouillet JP, Sarda P, Maudelonde T, Pujol P.

Cancer Genet Cytogenet. 2004 Dec;155(2):149-51.

PMID:
15571801
19.

Assessment of RNA quality extracted from laser-captured tissues using miniaturized capillary electrophoresis.

Copois V, Bret C, Bibeau F, Brouillet JP, Del Rio M, Berthe ML, Maudelonde T, Boulle N.

Lab Invest. 2003 Apr;83(4):599-602. No abstract available.

PMID:
12695563
20.

Mannose-6-phosphate/insulin-like growth factor-II receptor expression levels during the progression from normal human mammary tissue to invasive breast carcinomas.

Berthe ML, Esslimani Sahla M, Roger P, Gleizes M, Lemamy GJ, Brouillet JP, Rochefort H.

Eur J Cancer. 2003 Mar;39(5):635-42.

PMID:
12628843
21.

IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells.

Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F, Lazennec G.

Oncogene. 2003 Jan 16;22(2):256-65.

22.

Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis.

Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, Garcia M, Liaudet-Coopman E.

Oncogene. 2002 Aug 29;21(38):5951-5.

23.

[Genetic alterations of transcription cofactors in solid tumors].

Rouayrenc JF, Castet A, Rey JM, Brouillet JP, Pujol P, Vignon F, Maudelonde T, Cavaillès V.

Bull Cancer. 2002 Apr;89(4):357-64. Review. French.

24.

Novel germline RET mutation segregating with papillary thyroid carcinomas.

Rey JM, Brouillet JP, Fonteneau-Allaire J, Boneu A, Bastié D, Maudelonde T, Pujol P.

Genes Chromosomes Cancer. 2001 Dec;32(4):390-1.

PMID:
11746981
25.

Analysis of the potential contribution of estrogen receptor (ER) beta in ER cytosolic assay of breast cancer.

Brouillet JP, Dujardin MA, Chalbos D, Rey JM, Grenier J, Lamy PJ, Maudelonde T, Pujol P.

Int J Cancer. 2001 Jul 20;95(4):205-8.

26.

A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma.

Pujol P, Daures JP, Brouillet JP, Chang S, Rouanet P, Bringer J, Grenier J, Maudelonde T.

Cancer. 2001 May 15;91(10):1854-61.

PMID:
11346866
27.

Evi-1 transforming and repressor activities are mediated by CtBP co-repressor proteins.

Palmer S, Brouillet JP, Kilbey A, Fulton R, Walker M, Crossley M, Bartholomew C.

J Biol Chem. 2001 Jul 13;276(28):25834-40. Epub 2001 Apr 27.

28.

Semiquantitative reverse transcription-polymerase chain reaction to evaluate the expression patterns of genes involved in the oestrogen pathway.

Rey JM, Pujol P, Callier P, Cavailles V, Freiss G, Maudelonde T, Brouillet JP.

J Mol Endocrinol. 2000 Jun;24(3):433-40.

PMID:
10828836
30.

[Anti-estrogens, selective estrogen receptor modulators (SERM), tibolone: modes of action].

Maudelonde T, Brouillet JP, Pujol P.

Contracept Fertil Sex. 1999 Sep;27(9):620-4. Review. French.

PMID:
10540506
32.

Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.

Pujol P, Daurès JP, Brouillet JP, Maudelonde T, Rochefort H, Grenier J.

Br J Cancer. 1999 Feb;79(5-6):909-14.

33.

Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay.

Brouillet JP, Dufour F, Lemamy G, Garcia M, Schlup N, Grenier J, Mani JC, Rochefort H.

Cancer. 1997 Jun 1;79(11):2132-6.

PMID:
9179059
34.

Both estradiol and tamoxifen decrease proliferation and invasiveness of cancer cells transfected with a mutated estrogen receptor.

Garcia M, Derocq D, Platet N, Bonnet S, Brouillet JP, Touitou I, Rochefort H.

J Steroid Biochem Mol Biol. 1997 Apr;61(1-2):11-7.

PMID:
9328205
35.

Biological and clinical significance of cathepsin D in breast cancer metastasis.

Garcia M, Platet N, Liaudet E, Laurent V, Derocq D, Brouillet JP, Rochefort H.

Stem Cells. 1996 Nov;14(6):642-50. Review.

36.

Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay.

Roger P, Montcourrier P, Maudelonde T, Brouillet JP, Pages A, Laffargue F, Rochefort H.

Hum Pathol. 1994 Sep;25(9):863-71.

PMID:
8088760
37.

Cathepsin D cytosolic assay and immunohistochemical quantification in human prostate tumors.

Chambon M, Rebillard X, Rochefort H, Brouillet JP, Baldet P, Guiter J, Maudelonde T.

Prostate. 1994 Jun;24(6):320-5.

PMID:
7516070
39.

In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer.

Maudelonde T, Escot C, Pujol P, Rouanet P, Defrenne A, Brouillet JP, Rochefort H.

Eur J Cancer. 1994;30A(14):2049-53.

PMID:
7857701
40.

Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group.

Fernö M, Baldetorp B, Borg A, Brouillet JP, Olsson H, Rochefort H, Sellberg G, Sigurdsson H, Killander D.

Eur J Cancer. 1994;30A(14):2042-8.

PMID:
7857700
41.

A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol.

Pujol P, Maudelonde T, Daures JP, Rouanet P, Brouillet JP, Pujol H, Rochefort H.

Cancer. 1993 Mar 15;71(6):2006-12.

PMID:
8443752
42.

Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D.

Brouillet JP, Spyratos F, Hacene K, Fauque J, Freiss G, Dupont F, Maudelonde T, Rochefort H.

Eur J Cancer. 1993;29A(9):1248-51.

PMID:
8343262
43.

Biocompatibility of an enamel-dentin adhesive.

Elbaum R, Remusat M, Brouillet JL.

Quintessence Int. 1992 Nov;23(11):773-82.

PMID:
1305294
44.

Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival.

Duffy MJ, Reilly D, Brouillet JP, McDermott EW, Faul C, O'Higgins N, Fennelly JJ, Maudelonde T, Rochefort H.

Clin Chem. 1992 Oct;38(10):2114-6.

45.

Immunostaining of cathepsin D in breast cancer: quantification by computerised image analysis and correlation with cytosolic assay.

Maudelonde T, Brouillet JP, Roger P, Giraudier V, Pages A, Rochefort H.

Eur J Cancer. 1992;28A(10):1686-91.

PMID:
1389486
46.

Increased plasma cathepsin D concentration in hepatic carcinoma and cirrhosis but not in breast cancer.

Brouillet JP, Hanslick B, Maudelonde T, Pivat MT, Grenier J, Blanc F, Rochefort H.

Clin Biochem. 1991 Dec;24(6):491-6.

PMID:
1663431
47.

A histologic study of the biocompatibility of a dentinal bonding system.

Elbaum R, Pignoly C, Brouillet JL.

Quintessence Int. 1991 Nov;22(11):901-10.

PMID:
1812514
48.

[Aging of the dental pulp].

Badillo F, Brouillet JL.

Rev Fr Endod. 1991 Sep;10(3):41-54. French.

PMID:
1816607
49.

Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.

Le Roy X, Escot C, Brouillet JP, Theillet C, Maudelonde T, Simony-Lafontaine J, Pujol H, Rochefort H.

Oncogene. 1991 Mar;6(3):431-7.

PMID:
1707153
50.

Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings.

Duffy MJ, Brouillet JP, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Maudelonde T, Rochefort H.

Clin Chem. 1991 Jan;37(1):101-4.

Supplemental Content

Loading ...
Support Center